Literature DB >> 11994474

Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity.

Diane E Kawa1, Richard S Stephens.   

Abstract

The outer membrane protein PorB is a conserved chlamydial protein that functions as a porin and is capable of eliciting neutralizing Abs. A topological antigenic map was developed using overlapping synthetic peptides representing the Chlamydia trachomatis PorB sequence and polyclonal immune sera. To identify which antigenic determinants were surface accessible, monospecific antisera were raised to the PorB peptides and were used in dot-blot and ELISA-based absorption studies with viable chlamydial elementary bodies (EBs). The ability of the surface-accessible antigenic determinants to direct neutralizing Ab responses was investigated using standardized in vitro neutralization assays. Four major antigenic clusters corresponding to Phe(34)-Leu(59) (B1-2 and B1-3), Asp(112) -Glu(145) (B2-3 and B2-4), Gly(179)-Ala(225) (B3-2 to B3-4), and Val(261)-Asn(305) (B4-4 to B5-2) were identified. Collectively, the EB absorption and dot-blot assays established that the immunoreactive PorB Ags were exposed on the surface of chlamydial EBs. Peptide-specific antisera raised to the surface-accessible Ags neutralized chlamydial infectivity and demonstrated cross-reactivity to synthetic peptides representing analogous C. pneumoniae PorB sequences. Furthermore, neutralization of chlamydial infectivity by C. trachomatis PorB antisera was inhibited by synthetic peptides representing the surface-exposed PorB antigenic determinants. These findings demonstrate that PorB Ags may be useful for development of chlamydial vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994474     DOI: 10.4049/jimmunol.168.10.5184

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

3.  Induction of immune memory by a multisubunit chlamydial vaccine.

Authors:  F O Eko; E Ekong; Q He; C M Black; J U Igietseme
Journal:  Vaccine       Date:  2010-12-22       Impact factor: 3.641

4.  Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.

Authors:  Qing He; Luis Martinez-Sobrido; Francis O Eko; Peter Palese; Adolfo Garcia-Sastre; Deborah Lyn; Daniel Okenu; Claudiu Bandea; Godwin A Ananaba; Carolyn M Black; Joseph U Igietseme
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

Review 5.  Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles.

Authors:  Rajnish Sahu; Richa Verma; Saurabh Dixit; Joseph U Igietseme; Carolyn M Black; Skyla Duncan; Shree R Singh; Vida A Dennis
Journal:  Expert Rev Vaccines       Date:  2018-02-06       Impact factor: 5.217

6.  Nucleotide and phylogenetic analyses of the Chlamydia trachomatis ompA gene indicates it is a hotspot for mutation.

Authors:  Brian W Brunelle; George F Sensabaugh
Journal:  BMC Res Notes       Date:  2012-01-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.